Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,054 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Alectinib Resistance in ALK-Rearranged Lung Cancer by Dual Salvage Signaling in a Clinically Paired Resistance Model.
Tsuji T, Ozasa H, Aoki W, Aburaya S, Funazo T, Furugaki K, Yoshimura Y, Ajimizu H, Okutani R, Yasuda Y, Nomizo T, Uemasu K, Hasegawa K, Yoshida H, Yagi Y, Nagai H, Sakamori Y, Ueda M, Hirai T, Kim YH. Tsuji T, et al. Among authors: yoshimura y. Mol Cancer Res. 2019 Jan;17(1):212-224. doi: 10.1158/1541-7786.MCR-18-0325. Epub 2018 Aug 31. Mol Cancer Res. 2019. PMID: 30171175
Molecular targeting of HER2-overexpressing biliary tract cancer cells with trastuzumab emtansine, an antibody-cytotoxic drug conjugate.
Yamashita-Kashima Y, Yoshimura Y, Fujimura T, Shu S, Yanagisawa M, Yorozu K, Furugaki K, Higuchi R, Shoda J, Harada N. Yamashita-Kashima Y, et al. Among authors: yoshimura y. Cancer Chemother Pharmacol. 2019 Apr;83(4):659-671. doi: 10.1007/s00280-019-03768-8. Epub 2019 Jan 18. Cancer Chemother Pharmacol. 2019. PMID: 30659304
YAP1 mediates survival of ALK-rearranged lung cancer cells treated with alectinib via pro-apoptotic protein regulation.
Tsuji T, Ozasa H, Aoki W, Aburaya S, Yamamoto Funazo T, Furugaki K, Yoshimura Y, Yamazoe M, Ajimizu H, Yasuda Y, Nomizo T, Yoshida H, Sakamori Y, Wake H, Ueda M, Kim YH, Hirai T. Tsuji T, et al. Among authors: yoshimura y. Nat Commun. 2020 Jan 3;11(1):74. doi: 10.1038/s41467-019-13771-5. Nat Commun. 2020. PMID: 31900393 Free PMC article.
Combination efficacy of pertuzumab and trastuzumab for trastuzumab emtansine-resistant cells exhibiting attenuated lysosomal trafficking or efflux pumps upregulation.
Yamashita-Kashima Y, Shu S, Osada M, Fujimura T, Yoshiura S, Harada N, Yoshimura Y. Yamashita-Kashima Y, et al. Among authors: yoshimura y. Cancer Chemother Pharmacol. 2020 Nov;86(5):641-654. doi: 10.1007/s00280-020-04138-5. Epub 2020 Sep 30. Cancer Chemother Pharmacol. 2020. PMID: 32997196 Free PMC article.
2,054 results